Navigation Links
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
Date:6/3/2011

ROCKVILLE, Md., June 3, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.   The data were presented by the principal investigator for the study, Dr. Ursula A. Matulonis, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine, Harvard Medical School, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011 in Chicago, Illinois.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer.  The study was conducted at six sites in the United States and Canada and included Dana-Farber Cancer Institute, Indiana University Melvin & Bren Simon Cancer Center, University of Chicago Medical Center, Memorial Sloan-Kettering Cancer Center, University of Colorado Cancer Center, and Princess Margaret Hospital.  Sixty-four patients were enrolled of which 57 were evaluable at the time of the presentation.  The primary endpoint for the study was progression-free survival rate at six months.  Secondary end-points include response rate, duration of response, and overall survival.  

ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent.  Interim data from 57 evaluable patients showed a six-month progression free survival rate of 19%.  Of the evaluable patients, four patients achieved a partial response and 30 patients achieved stable disease as measured by RECIST v1.1.
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
5. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
6. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
7. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
8. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
9. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
10. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
11. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 Investor-Edge ... (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... on these five companies can be accessed at: ... October 23, 2014, ended on a positive note as ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Calif., March 30 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... shareholders, prospective investors and interested parties in Zurich, Switzerland ... will be to update the investment community on the ... be available to answer shareholder questions along with ...
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... be presenting at the upcoming 16th ... at New York City,s Millennium Broadway Hotel and Conference Center. ... April 2, 2009 at 9:30 a.m. EDT.Individuals can listen to ...
... Graeme Clark Scholarship WinnersDENVER, March 30 Cochlear ... today announced the winners of the 2009 Graeme ... Cochlear Scholarship Foundation has recognized the remarkable achievements ... implant - a small electronic device that can ...
Cached Biology Technology:Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 3Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 4Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 5
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/16/2014)... 16, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... including Wocket™, the Smart Wallet, at the 13 th ... a leading global conference on the intersection of technology ... Mark Anderson , founder and publisher of the Strategic ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... honors four leaders in biomedical and health informatics ... Annual Symposium, Oct. 22-26, an event expected to ... over the coming week. The Signature Awards highlight ... sector have had significant, positive impact. , ...
... 20 OCTOBER 2011 EMBO today acknowledges the outstanding ... by awarding them life-long EMBO membership. Election to ... excellence and the exceptional achievements made by a life ... 1,500 of the best researchers in Europe and around ...
... COLUMBIA, Mo. The face and brain develop ... the embryo and continuing through adolescence. Now, University of ... characteristics of children with autism compared to those of ... the origins of autism. "There is ...
Cached Biology News:AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 346 outstanding life scientists elected to EMBO membership 2Autistic facial characteristics identified 2
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
... ST-190-XY is an automated instrument with a ... in real-time using light or fluorescence microscopy. ... muscle, and fibroblast cells can be simulated ... X and Y axis of our strain ...
... Our Smart Solutions has now entered the ... (HCS) by partnering up with Cellomics, Inc. ... the integration of Beckman Coulter‘s automated solutions ... deeper biological information at the sub-cellular level. ...
Biology Products: